Security
RADIOPHARM THERANOSTICS LTD Ordinary Shares · RDPTF
RDPTFOTCCommon stockCurrentCIK 1949257Updated Nov 6, 2026
RDPTF price & chart
Loading TradingView…
OTC:RDPTF on TradingView ↗About the company
Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and five Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain metastases. Learn more at radiopharmtheranostics.com
In the news
No coverage from other publishers is available.
Seeking Alpha
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
cash flow · annual statements
| Line item | FY 2025 |
|---|---|
| Cash flows from operating activities: | |
| Profit or LossUSD | -38,342,457Source |
| Additional Financial Items | |
| AdjustmentsForFinanceCostsUSD | -285Source |
| AdjustmentsForFinanceIncomeUSD | -888,196Source |
| AdjustmentsForSharebasedPaymentsUSD | 1,895,348Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsUSD | -138,141Source |
| GeneralAndAdministrativeExpenseUSD | 14,638,013Source |
| InterestReceivedClassifiedAsOperatingActivitiesUSD | 800,309Source |
| ProceedsFromIssuingSharesUSD | 53,977,902Source |
income statement · annual statements
| Line item | FY 2025 |
|---|---|
| Cost of Goods and Services Sold | —Source |
| Total RevenueUSD | 3,633,422Source |
| Additional Financial Items | |
| BasicEarningsLossPerShareUSD per share | -1.76Source |
| CurrentTaxExpenseIncomeUSD | 103,292Source |
| DilutedEarningsLossPerShareUSD per share | -1.76Source |
| FinanceCostsUSD | 65,300Source |
| GeneralAndAdministrativeExpenseUSD | 14,638,013Source |
| GrossProfitUSD | 39,276Source |
| IncomeTaxExpenseContinuingOperationsUSD | 103,292Source |
| OtherIncomeUSD | 10,256,740Source |
| ProfitLossBeforeTaxUSD | -38,239,165Source |
| ProfitLossFromOperatingActivitiesUSD | -38,173,865Source |
| ResearchAndDevelopmentExpenseUSD | 27,515,194Source |
Offerings
Registration 333-298912
Filing attachments
ea031087301ex99-1.htm · 6-K · 2026-11-04
Exhibit 99.1 ASX ANNOUNCEMENT 4 November 2026 ──────────────────── Radiopharm Theranostics Announces Alignment with U.S. FDA on Single Pivotal Phase 3 Trial for RAD101 in Diagnosis of Brain Metastases Single, multicenter Phase 3 imaging trial of approximately 280 patients with brain metastases designed to demonstrate sensitivity and specificity above prespecified performance thresholds. Radiopharm Theranostics advancing preparations for Phase 3 study with clinical supply of 18F-labele…
Read attachment ↗ea031030701ex99-1.htm · 6-K · 2026-10-30
Exhibit 99.1 ASX ANNOUNCEMENT 30 October 2026 ──────────────────── Radiopharm Theranostics Reports Business Update Phase 3 imaging trial of RAD101 in recurrent brain metastases from solid tumors expected to initiate in 1Q27 following successful end-of-phase 2 meeting with U.S. Food and Drug Administration Reported positive Phase 1 imaging data for RAD301, supporting advancement toward Phase 2 development in pancreatic ductal adenocarcinoma Advanced to fourth dosing cohort in ongoing …
Read attachment ↗ea030977501ex99-1.htm · 6-K · 2026-10-27
Exhibit 99.1 Notice of Annual General Meeting Radiopharm Theranostics Limited ACN 647 877 889 Notice of Annual General Meeting Radiopharm Theranostics Limited ACN 647 877 889 Notice is given that the Annual General Meeting of Radiopharm Theranostics Limited ACN 647 877 889 ( Company ) will be held at: Location Virtually (online) via the Automic Investor Portal at investor.automic.com.au by following the instructions contained in this Notice of Meeting Date …
Read attachment ↗ea030961801ex99-1.htm · 6-K · 2026-10-26
Exhibit 99.1 ASX ANNOUNCEMENT 26 October 2026 ──────────────────── Radiopharm receives $8M advance on FY26 R&D tax incentive Sydney, Australia - 26 October 2026 - Radiopharm Theranostics Limited (ASX: RAD; Nasdaq:RADX), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce it has received $8,000,000 from Rockford Capital under a funding facility secured against Radiopharm’s anticipated FY26 Research and De…
Read attachment ↗ea030912301ex99-1.htm · 6-K · 2026-10-20
Exhibit 99.1 Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001. Amended 01/01/11 Name Radiopharm of Entity: Theranostics Limited (ASX: RAD) ABN: 57 647 877 889 We (the entity) give ASX th…
Read attachment ↗ea030912301ex99-2.htm · 6-K · 2026-10-20
Exhibit 99.2 Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities Announcement Summary Entity name RADIOPHARM THERANOSTICS LIMITED Date of this announcement Tuesday October 20, 2026 The +securities the subject of this notification are: +Securities issued under an +employee incentive scheme that are subject to a restriction on transfer and are not being quoted on ASX until the restriction ends Total number of +securities to be issued/transferred …
Read attachment ↗